Lecanemab has not been as widely tested in Black patients.
Almost anyone can take this quick test for Alzheimer’s without even going to the doctor. It’s a terrible idea.
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.